227 related articles for article (PubMed ID: 33536913)
1. Curcumin Nanoparticle Enhances the Anticancer Effect of Cisplatin by Inhibiting PI3K/AKT and JAK/STAT3 Pathway in Rat Ovarian Carcinoma Induced by DMBA.
Sandhiutami NMD; Arozal W; Louisa M; Rahmat D; Wuyung PE
Front Pharmacol; 2020; 11():603235. PubMed ID: 33536913
[TBL] [Abstract][Full Text] [Related]
2. Nanocurcumin preserves kidney function and haematology parameters in DMBA-induced ovarian cancer treated with cisplatin via its antioxidative and anti-inflammatory effect in rats.
Louisa M; Wanafri E; Arozal W; Sandhiutami NMD; Basalamah AM
Pharm Biol; 2023 Dec; 61(1):298-305. PubMed ID: 36708211
[TBL] [Abstract][Full Text] [Related]
3. Curcumin and resveratrol inhibit chemoresistance in cisplatin-resistant epithelial ovarian cancer cells via targeting P13K pathway.
Muhanmode Y; Wen MK; Maitinuri A; Shen G
Hum Exp Toxicol; 2022; 41():9603271221095929. PubMed ID: 35722665
[TBL] [Abstract][Full Text] [Related]
4. Curcumin-Mediated Apoptotic Cell Death in Papillary Thyroid Cancer and Cancer Stem-Like Cells through Targeting of the JAK/STAT3 Signaling Pathway.
Khan AQ; Ahmed EI; Elareer N; Fathima H; Prabhu KS; Siveen KS; Kulinski M; Azizi F; Dermime S; Ahmad A; Steinhoff M; Uddin S
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936675
[TBL] [Abstract][Full Text] [Related]
5. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth.
Yallapu MM; Maher DM; Sundram V; Bell MC; Jaggi M; Chauhan SC
J Ovarian Res; 2010 Apr; 3():11. PubMed ID: 20429876
[TBL] [Abstract][Full Text] [Related]
6. Fuzheng Jiedu Decoction Induces Apoptosis and Enhances Cisplatin Efficacy in Ovarian Cancer Cells
Yang H; Li H; Lu S; Shan S; Guo Y
Biomed Res Int; 2022; 2022():5739909. PubMed ID: 35281608
[TBL] [Abstract][Full Text] [Related]
7. Curcumin and resveratrol inhibit chemoresistance in cisplatin-resistant epithelial ovarian cancer cells via targeting P13K pathway.
Muhanmode Y; Wen MK; Maitinuri A; Shen G
Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S861-S868. PubMed ID: 34791915
[TBL] [Abstract][Full Text] [Related]
8. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P
Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917
[TBL] [Abstract][Full Text] [Related]
9. A novel curcumin analog (H-4073) enhances the therapeutic efficacy of cisplatin treatment in head and neck cancer.
Kumar B; Yadav A; Hideg K; Kuppusamy P; Teknos TN; Kumar P
PLoS One; 2014; 9(3):e93208. PubMed ID: 24675768
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effect of Curcumin and Nanocurcumin on Nephroprotection at Cisplatin-induced Rats.
Sandhiutami NMD; Arozal W; Louisa M; Rahmat D; Mandy T
J Pharm Bioallied Sci; 2019 Dec; 11(Suppl 4):S567-S573. PubMed ID: 32148365
[TBL] [Abstract][Full Text] [Related]
11. The inhibitory effect of curcumin via fascin suppression through JAK/STAT3 pathway on metastasis and recurrence of ovary cancer cells.
Kim MJ; Park KS; Kim KT; Gil EY
BMC Womens Health; 2020 Nov; 20(1):256. PubMed ID: 33213437
[TBL] [Abstract][Full Text] [Related]
12. Molecular Targets of Curcumin and Its Therapeutic Potential for Ovarian Cancer.
Mohamadian M; Bahrami A; Moradi Binabaj M; Asgharzadeh F; Ferns GA
Nutr Cancer; 2022; 74(8):2713-2730. PubMed ID: 35266849
[TBL] [Abstract][Full Text] [Related]
13. Curcumin Prevents Epithelial-to Mesenchymal Transition-Mediated Ovarian Cancer Progression through NRF2/ETBR/ET-1 Axis and Preserves Mitochondria Biogenesis in Kidney after Cisplatin Administration.
Barinda AJ; Arozal W; Sandhiutami NMD; Louisa M; Arfian N; Sandora N; Yusuf M
Adv Pharm Bull; 2022 Jan; 12(1):128-141. PubMed ID: 35517894
[No Abstract] [Full Text] [Related]
14. Nanocurcumin alleviates insulin resistance and pancreatic deficits in polycystic ovary syndrome rats: Insights on PI3K/AkT/mTOR and TNF-α modulations.
Abuelezz NZ; Shabana ME; Abdel-Mageed HM; Rashed L; Morcos GNB
Life Sci; 2020 Sep; 256():118003. PubMed ID: 32589998
[TBL] [Abstract][Full Text] [Related]
15. Curcumin Suppresses M2 Macrophage-derived Paclitaxel Chemoresistance through Inhibition of PI3K-AKT/STAT3 Signaling.
Deswal B; Bagchi U; Kapoor S
Anticancer Agents Med Chem; 2024; 24(2):146-156. PubMed ID: 37957871
[TBL] [Abstract][Full Text] [Related]
16. Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K-AKT Pathway and Activating the AMPK-ROS Pathway.
Wei X; Shi J; Lin Q; Ma X; Pang Y; Mao H; Li R; Lu W; Wang Y; Liu P
Front Oncol; 2021; 11():642229. PubMed ID: 33816292
[No Abstract] [Full Text] [Related]
17. The theranostic potentialities of bioavailable nanocurcumin in oral cancer management.
Essawy MM; Mohamed MM; Raslan HS; Rafik ST; Awaad AK; Ramadan OR
BMC Complement Med Ther; 2022 Nov; 22(1):309. PubMed ID: 36424593
[TBL] [Abstract][Full Text] [Related]
18. Demethoxycurcumin-Loaded Chitosan Nanoparticle Downregulates DNA Repair Pathway to Improve Cisplatin-Induced Apoptosis in Non-Small Cell Lung Cancer.
Chen YY; Lin YJ; Huang WT; Hung CC; Lin HY; Tu YC; Liu DM; Lan SJ; Sheu MJ
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563166
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
20. Nanotechnological synergy of mangiferin and curcumin in modulating PI3K/Akt/mTOR pathway: a novel front in ovarian cancer precision therapeutics.
Alharbi HM; Alqahtani T; Alamri AH; Kumarasamy V; Subramaniyan V; Babu KS
Front Pharmacol; 2023; 14():1276209. PubMed ID: 38239204
[No Abstract] [Full Text] [Related]
[Next] [New Search]
